.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Daiichi Sankyo
Citi
McKesson
Accenture
Cantor Fitzgerald
Argus Health
Teva
Deloitte

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205223

« Back to Dashboard
NDA 205223 describes NUVESSA, which is a drug marketed by Chemo Research Sl and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug. Additional details are available on the NUVESSA profile page.

The generic ingredient in NUVESSA is metronidazole. There are eighteen drug master file entries for this compound. Eighty-four suppliers are listed for this compound. Additional details are available on the metronidazole profile page.

Summary for 205223

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:5
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 205223

Ingredient-typeNitroimidazoles

Medical Subject Heading (MeSH) Categories for 205223

Suppliers and Packaging for NDA: 205223

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NUVESSA
metronidazole
GEL;VAGINAL 205223 NDA Allergan, Inc. 0023-5920 0023-5920-05 1 APPLICATOR in 1 CARTON (0023-5920-05) > 5 g in 1 APPLICATOR
NUVESSA
metronidazole
GEL;VAGINAL 205223 NDA Actavis Pharma, Inc. 52544-157 52544-157-26 1 PACKAGE in 1 CARTON (52544-157-26) > 1 APPLICATOR in 1 PACKAGE > 5 g in 1 APPLICATOR

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL;VAGINALStrength1.3%
Approval Date:Mar 24, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 24, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Feb 19, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jun 27, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF BACTERIAL VAGINOSIS


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
Covington
Healthtrust
Chubb
Harvard Business School
Express Scripts
US Department of Justice
Cantor Fitzgerald
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot